Navigation Links
Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens' Hospital
Date:2/26/2008

EMERYVILLE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced the amendment of its license and cooperation agreement with Merz Pharmaceuticals GmbH (Merz) and Childrens' Medical Center Corporation ("CMCC") relating to memantine, which is currently marketed in the United States as Namenda(TM) and in Europe as Ebixa(TM).

The amendment modifies the terms of the royalties to be paid to the company on sales of memantine, including discontinuing the payment of royalties on sales of memantine for Alzheimer's disease outside of the United States beginning in the fourth quarter of 2007 (for which the company is due to receive a royalty payment in April 2008) and providing for a staged reduction in the royalty rates to be paid to the company and CMCC on sales of memantine in the United States beginning in the third quarter of 2008. In addition, the amendment provides that neither CMCC nor Merz will give notice of termination of the agreement under the section relating to the development of memantine for the CMCC indications before July 1, 2009 or to be effective before January 1, 2010.

"We felt it was important to agree to this amendment to reduce the uncertainty relating to ability of Merz and CMCC to terminate the agreement on six months' notice and to give us greater assurance that we will continue to receive royalty payments on US sales of memantine for at least the next two years, which will be a critical period for our company as we complete our pivotal phase 3 clinical trials of Viprinex(TM) for ischemic stroke," said Paul E. Freiman, President and CEO of Neurobiological Technologies. "As we effectively receive our payments two quarters after the memantine sales are made, this means that we should receive royalty payments from Merz, albeit at reduced rates, until the second quarter of 2010."

The company also announced that, in connection with entering into the amendment, it had received the payment from Merz due on January 30, 2008 of the royalties on sales of memantine in the third quarter of 2007 in the amount of $2,161,228.

About Neurobiological Technologies, Inc.

NTI is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate is Viprinex(TM) (ancrod), a novel multi-targeted agent currently undergoing pivotal Phase 3 clinical testing for the potential treatment of acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on Merz and its marketing partners and other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission.

Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
2. Neurobiological Technologies Sets Date for Research and Development Day
3. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
4. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
5. Neurobiological Technologies Sets Date for Second Quarter Financial Results
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
8. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
9. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
10. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
11. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Biotheranostics today announced ... role of the Breast Cancer Index (BCI) in ... cancer are most at-risk for disease recurrence and ... results from three studies advancing the understanding of ... to tumor biology and inform decisions related to ...
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... -- Oxford Gene Technology (OGT), The ... range with the launch of the SureSeq myPanel™ NGS Custom ... in familial hypercholesterolemia (FH). The panel delivers single nucleotide variation ... small panel and allows customisation by ,mix and match, of ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This single ... engineered to radically streamline culture processes, minimize processing time, significantly decrease production ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
(Date:12/2/2016)... The report "Biometric Vehicle Access ... (Iris Recognition System), Vehicle Type (Passenger Car, Battery ... 2021", published by MarketsandMarkets, the market is estimated ... is projected to grow to USD 854.8 Million ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):